Trial Profile
A Multicenter, Open-Label Study to Evaluate Ovarian Follicular Activity and Hormone Levels With the Oral Contraceptive Regimen DR-102 Compared to Two 28-day Oral Contraceptive Regimens Containing Different Synthetic Progestins.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Dec 2021
Price :
$35
*
At a glance
- Drugs Ethinylestradiol/desogestrel (Primary) ; Drospirenone/ethinylestradiol; Ethinylestradiol; Ethinylestradiol/levonorgestrel
- Indications Pregnancy
- Focus Pharmacodynamics
- Sponsors Teva Branded Pharmaceutical Products R&D
- 28 May 2013 Status changed from active, no longer recruiting to completed, based on 61st ACOG abstract.
- 08 May 2013 Results presented at the 61st Annual Clinical Meeting of the American College of Obstetricians and Gynecologists.
- 08 May 2013 Results were presented at the 61st Annual Clinical Meeting of the American Congress of Obstetricians and Gynecologists (ACOG), according to a Teva Women's Health media release.